Fate Therapeutics officer sells shares for taxes

Fate Therapeutics’ Chief Legal and Compliance Officer, Cindy Tahl, reported a sale of 38,800 shares of common stock on August 4, 2026 at a weighted average price of $2.4589 per share, with prices ranging from $2.415 to $2.540.

Rhea-AI Filing Summary

Fate Therapeutics’ Chief Legal and Compliance Officer, Cindy Tahl, reported a sale of 38,800 shares of common stock on August 4, 2026 at a weighted average price of $2.4589 per share, with prices ranging from $2.415 to $2.540.

The shares were sold to cover tax withholding obligations in connection with the vesting of 75,000 shares of common stock underlying RSUs granted on July 29, 2024, through automatic “sell-to-cover” transactions executed under an irrevocable election and not at her discretion. After these transactions, she directly holds 589,355 shares of Fate Therapeutics common stock.

Insider Trade Summary

Net Seller: 38,800 shares

Net Sell 1 txn

Insider TAHL CINDY

Role See Remarks

Sold 38,800 shs ($95K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	38,800	$2.4589	$95K

Holdings After Transaction: Common Stock — 589,355 shares (Direct)

Footnotes (2)

1. F1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
2. F2. Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Key Figures

Shares sold: 38,800 shares Weighted average sale price: $2.4589 per share Sale price range: $2.415–$2.540 per share +2 more

5 metrics

Shares sold 38,800 shares Sale of common stock on August 4, 2026 by Cindy Tahl

Weighted average sale price $2.4589 per share Weighted average price for the 38,800 shares sold

Sale price range $2.415–$2.540 per share Price range for shares included in the weighted average sale price

Shares held after transaction 589,355 shares Direct Fate Therapeutics common stock holdings following the sale

RSU-related vesting shares 75,000 shares Shares of common stock underlying RSUs whose vesting triggered the tax-withholding sale

Key Terms

sell-to-cover, RSUs, weighted average sale price, tax withholding obligations

4 terms

sell-to-cover financial

"through "sell-to-cover" transactions to satisfy tax withholding"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

RSUs financial

"vesting of 75,000 shares of Common Stock underlying RSUs granted"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

weighted average sale price financial

"Represents the weighted average sale price of the shares"

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sale did FATE report for executive Cindy Tahl?

Cindy Tahl, Fate Therapeutics’ Chief Legal and Compliance Officer, sold 38,800 shares of common stock on August 4, 2026 at a weighted average price of $2.4589 per share, with individual trade prices ranging from $2.415 to $2.540.

Why did Cindy Tahl’s sale of FATE shares occur?

The 38,800 shares were sold to cover tax withholding obligations arising from the vesting of 75,000 shares of common stock underlying RSUs granted on July 29, 2024, via automatic sell-to-cover transactions under an irrevocable election.

Was Cindy Tahl’s FATE stock sale discretionary trading?

No. The filing states the sales were automatically executed pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations and were not made at the discretion of the reporting person, Cindy Tahl.

How many FATE shares does Cindy Tahl hold after the reported sale?

Following the tax-related sale, Cindy Tahl directly holds 589,355 shares of Fate Therapeutics common stock. This post-transaction ownership figure reflects her remaining direct holdings after the 38,800 shares were sold to cover tax withholding obligations.

What price range applied to Cindy Tahl’s FATE share sale?

The reported weighted average sale price was $2.4589 per share. Individual trades occurred within a price range from $2.415 to $2.540 per share, and the insider can provide detailed breakdowns of shares sold at each price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:04 PM Accepted by SEC EDGAR 08/05/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAHL CINDY

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2026		S(1)		38,800	D	$2.4589(2)	589,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.

2. Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Remarks:

Chief Legal and Compliance Officer

	/s/ Cindy Tahl	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)